GlassScriptPhysician profile
Ryan Thomas Cardew
NPI 1457880460
$4,746.82
in general payments reported to CMS, 2019-2025
22 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.70 · 2023: $609 · 2024: $2,315 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,693.01 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.74 | 2023-2025 | Mavyret, Dalvance |
| Merck Sharp & Dohme LLC | $583.97 | 2023-2025 | Pifeltro, Zerbaxa, Dificid |
| Gilead Sciences, INC. | $535.50 | 2023-2025 | |
| Viiv Healthcare Company | $529.02 | 2023-2025 | Dovato, Apretude |
| La Jolla Pharmaceutical Company | $354.81 | 2024-2025 | Xerava, Zevtera, Xacduro |
| Shionogi INC | $328.68 | 2023-2025 | Fetroja |
| Ferring Pharmaceuticals INC. | $298.69 | 2023-2025 | Rebyota |
| Astellas Pharma US INC | $295.14 | 2023-2024 | Cresemba |
| Insmed, INC. | $164.24 | 2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $151.63 | 2023-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $149.29 | 2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $121.13 | 2023 | Livtencity |
| Theratechnologies INC. | $97.48 | 2023-2024 | Egrifta, Trogarzo |
| Tetraphase Pharmaceuticals, INC. | $54.20 | 2025 | |
| Aimmune Therapeutics, INC. | $51.99 | 2024-2025 | Vowst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.70 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $29.90 | 2024-2025 | Vibativ |
| Tersera Therapeutics LLC | $28.83 | 2025 | Quzyttir |
| Redhill Biopharma INC. | $26.98 | 2024 | Aemcolo, Talicia |
| Dynavax Technologies Corporation | $21.48 | 2024 | Heplisav-B |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Electromed, INC. | $15.31 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cardew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.